On2827October 2026, Brazil's judiciary ordered an investigation into possible financial support from abroad for Flávio Bolsonaro's presidential election campaign. The ruling signed bySupremeFederalJudgeCourt JusticeFlávio Dino

with Arab parties potentially playing a key role, although several Jewish parties had ruled out coalitions withthemthem. In the final count announced on 29 October, Yashar won 21 seats, second to Likud's 27, and neither Netanyahu's bloc (53 seats) nor the opposition lists including Yashar (48) reached the 61 needed for a majority

Despite early promise in its DNA vaccine technology, Inovio encountered significant setbacks, including an FDA clinical hold in 2021 on its COVID-19 candidate INO-4800 due to safety concerns from preclinical studies on potential plasmid DNA integration into the host genome, alongside broader challenges including the scalability of its electroporation device for large-scale manufacturing, leading to deprioritization of the program amid difficulties in advancing DNA-based vaccines beyond early-phase trials. The company has faced intellectual property disputes, such as a 2020 litigation with former partner GeneOne Life Science over DNA vaccine rights, and persistent funding pressures as a pre-revenue entity reliant on equity offerings and grants, resulting in stock volatility from pandemic-era hype to subsequent declines. Inovio's defining characteristic remains its focus on precision DNA engineering for targeted immuneactivation, though commercialization has been elusive,activation; after years without a marketed product, it received its first FDA approval on October 30, 2026, when INO-3107 was granted accelerated approval as Voceryq for adultswithnorecurrent respiratory papillomatosis, which the FDA described as the first plasmid DNA-based immunotherapyapprovedproducts to datein the United States,andongoing emphasis onthe company continues to emphasizeHPV therapeutics following pivots from broader infectious disease pursuits.